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Whole exome sequencing in 17 
consanguineous Iranian pedigrees 
expands the mutational spectrum 
of inherited retinal dystrophies
Atta Ur Rehman1,11, Neda Sepahi2,11, Nicola Bedoni1,11, Zeinab Ravesh3, 
Arash Salmaninejad4, Francesca Cancellieri5,6, Virginie G. Peter3,5,6,7, Mathieu Quinodoz3,5,6, 
Majid Mojarrad4, Alireza Pasdar4,8,9, Ali Ghanbari Asad2, Saman Ghalamkari10, Mehran Piran2, 
Mehrdad Piran2, Andrea Superti‑Furga1 & Carlo Rivolta3,5,6*
Inherited retinal dystrophies (IRDs) constitute one of the most heterogeneous groups of 
Mendelian human disorders. Using autozygome‑guided next‑generation sequencing methods 
in 17 consanguineous pedigrees of Iranian descent with isolated or syndromic IRD, we identified 
17 distinct genomic variants in 11 previously‑reported disease genes. Consistent with a recessive 
inheritance pattern, as suggested by pedigrees, variants discovered in our study were exclusively 
bi‑allelic and mostly in a homozygous state (in 15 families out of 17, or 88%). Out of the 17 variants 
identified, 5 (29%) were never reported before. Interestingly, two mutations (GUCY2D:c.564dup, 
p.Ala189ArgfsTer130 and TULP1:c.1199G > A, p.Arg400Gln) were also identified in four separate 
pedigrees (two pedigrees each). In addition to expanding the mutational spectrum of IRDs, our 
findings confirm that the traditional practice of endogamy in the Iranian population is a prime cause 
for the appearance of IRDs.
Inherited retinal dystrophies/degenerations (IRDs) are Mendelian disorders of the eye that affect approximately 
1 in 1500 people worldwide and constitute a major cause of inherited  blindness1. Mainly characterized by the 
progressive death of photoreceptor cells in the retina, IRDs present a high degree of genetic and phenotypic 
 heterogeneity2. So far, mutations in over 270 genes have been associated with various forms of IRDs (RetNet: 
https:// sph. uth. edu/ retnet/; accessed April 17, 2020); however, this list is constantly increasing. Sequencing of 
all exons and exon–intron boundaries of these genes has successfully contributed to the understanding of the 
genetic etiology of 50–70% of  patients3–5. Since a larger proportion of IRDs are caused by recessive  mutations6, 
next-generation sequencing (NGS) coupled with homozygosity mapping has further accelerated detection of 
candidate variants in consanguineous  pedigrees3.
Close-kin marital unions have long been practiced in the Iranian population as a cultural  feature7. In spite 
of a significant decline in consanguinity in Iran in recent years, prevalence of recessive genetic disorders is still 
high in the country, possibly due to the presence of marked population stratification that favors intra-community 
 marriages7,8. As a result, increased genomic homozygosity in specific societies or ethnic groups leads to the 
clinical observation of the effect of rare founder  mutations7,9. The present study was performed with the aim of 
characterizing genetically a cohort of 17 consanguineous Iranian families with IRDs.
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Methods
Enrollment of families and DNA extraction. This study was approved by the Ethics Committees of 
all our respective Institutions (the Ethikkommission Nordewest- and Zentralschweiz, the Ethics Committee of 
Mashhad University of Medical Sciences, the Ethics Commission of the Noncommunicable Diseases Research 
Center of Fasa University of Medical Sciences, and the Ethics Commission of the Canton de Vaud) and adhered 
to the principles of the Declaration of Helsinki. All individuals participating in this study were Iranian residents, 
who agreed in contributing to this study by signing a written informed consent form. Patients were clinically 
evaluated by local ophthalmologists and their medical records were maintained at their respective hospitals. 
Approximately 5.0 ml peripheral blood was collected using a EDTA K2 golden vac disposable vacuum blood col-
lection tube (Zhejiang Gondong Medical Technology, China) or were mixed with EDTA anticoagulant (Merck 
KGaA, Darmstadt, Germany) after sample collection. DNA was extracted from peripheral blood leukocytes 
following standard protocols. Quantitative assessment of DNA was made using a NanoDrop 1000 Spectropho-
tometer (Thermo Fisher Scientific, USA), whereas integrity was evaluated by running the DNA samples on a 1% 
agarose gel. Pedigrees were drawn with the help of  HaploPainter10.
Genetic analyses. Exome capture and library preparation was performed on one affected individual per 
family using the SureSelect Human All Exon v6 kit (Agilent, Santa Clara, CA, USA) and the HiSeq Rapid PE 
Cluster Kit v2 (Illumina, San Diego, CA, USA), from 2 μg genomic DNA. Whole-exome sequencing (WES) was 
performed at the Institute of Genomics of the University of Tartu (Estonia) using an Illumina HiSeq (HSQ-
700358) instrument. Bioinformatic analyses were performed as described  previously11. Briefly, raw reads were 
mapped to the human reference genome (hg19/GRCh37) using the Novoalign software (V3.08.00, Novocraft 
Technologies). Next, Picard (version 2.14.0-SNAPSHOT) was used to remove duplicate reads and Genome 
Analysis Toolkit (GATK) (version 3.8)  was used to perform base quality score recalibration on both single-
nucleotide variants and insertion–deletions. A VCF file with the variants was generated by HaplotypeCaller. 
They were annotated according to a specific in-house pipeline using mainly ANNOVAR  software12 (Oct 2019 
release) and splicing predictors:  spliceAI13,  MaxEntScan14, and Ada and RF scores from  dbscSNV15. Then, DNA 
variants were filtered to have less than 1% allelic frequency in  ExAC16,  gnomAD17, 1000  Genomes18, and GME 
(GME Variome http:// igm. ucsd. edu/ gme/ index. php). Variants were then retained according to their predicted 
impact on protein sequence and splicing of preRNA, according to ANNOVAR RefSeq annotation (missense, 
stopgain, frameshift or non-frameshift indels, or canonical splicing) and splicing predictors (MaxEntScan [mini-
mal change of 6], spliceAI [minimal score of 0.2] and dbscSNV-ADA [minimal score of 0.2]).
Autozygosity mapping was performed on WES data with  AutoMap19. Nomenclature of all the variants was 
confirmed through  VariantValidator20. Clinical significance of the variants was evaluated with the help of pub-
licly available databases such as  ClinVar21, the Human Gene Mutation Database (HGMD)22 and  Varsome23, as 
well as according to their frequency in available databases, e.g. the Genome Aggregation Database (gnomAD)17. 
Seven online in-silico methods were used to predict the pathogenicity of all variants. The online in-silico tools 
used included  MutationTaster24, Mutation  Assessor24, Polymorphism Phenotyping v2 (PolyPhen-2)25, Likeli-
hood Ratio Test (LRT)26, Sorting Intolerant from Tolerant (SIFT)27,  PROVEAN28, and Combined Annotation 
Dependent Depletion (CADD)29. Furthermore, all candidate variants were compared with data from Iranome, 
a database containing information from 800 exomes from individuals belonging to eight major ethnic groups 
in Iran (http:// www. irano me. ir/; accessed on April 19, 2020). Finally, Sanger sequencing was performed to 
validate all potentially pathogenic variants and to establish their causality through strict genotype–phenotype 
co-segregation within the available family members.
Results
Following WES analysis in 17 probands of Iranian descent, 16 of which were the direct offspring of consanguin-
eous unions (Fig. 1), we identified 17 distinct genetic variants in 11 genes linked to inherited retinal diseases 
(Tables 1 and 2). Of the 17 pedigrees, two families each were linked to disease-causing variants in CNGA3, 
GUCY2D, IQCB1, RDH12, RP1, and TULP1 genes, while only one family was found with causative variants in 
either USH1G, ABCA4, NMNAT1, CRB1, or BBS2 genes. The mutational spectrum across these 11 genes com-
prised 7 missense variants, 4 nonsense variants, 4 small insertion-deletions (Indels) or duplications leading to 
frameshifts, one canonical splice site variant and one synonymous variant with effect on splicing. As expected, 
most of the variants in our study were found in a homozygous state (in 15 families out of 17, or 88%). Compound 
heterozygosity was detected in two families (F009 and IRN_070, Tables 1, 2). Except for one homozygous allele 
in the RP1 gene (NM_006269.1:c.788-1G > A) in family IRN_039, all other homozygous pathogenic variants 
were found in genes that were located inside a so-called run of homozygosity (ROH), generally spanning more 
than one megabase (Mb) in size.  
Overall, 29% (5 out of 17 different alleles) of the variants reported here were previously unpublished. Similarly, 
8 of the total 17 distinct alleles had no gnomAD entry, while the others were all very rare, with no occurrence 
of homozygous individuals in the gnomAD database (Table 3). Interestingly, we identified two variants, each 
segregating homozygously in two separate pedigrees: GUCY2D (NM_000180.3:c.564dup, p.Ala189ArgfsTer130; 
families IRN_001 and IRN_042) and TULP1 (NM_003322.3:c.1199G > A, p.Arg400Gln; families F007 and F034).
All 7 missense variants with their predicted pathogenicity scores are listed in Table 3. While 6 of them 
were previously known to be pathogenic, including NMNAT1 (p.Glu257Lys)30, CNGA3 (p.Arg283Gln)31, CRB1 
(p.Cys201Arg)32, TULP1 (p.Arg400Gln)33, RDH12 (p.Arg239Trp)34, and CNGA3 (p.Arg277His)35, the remaining 
one, NMNAT1 (p.Ile174Phe), was novel. Additionally, segregation analysis within the available family members 
using Sanger sequencing revealed strict genotype–phenotype correlation for all nonsynonymous variants.
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Figure 1.  Pedigrees showing genotype–phenotype co-segregation for all detected variants. m, variant 
identified; + , wild-type allele.
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Furthermore, we identified four already published nonsense pathogenic variants in our cohort, including 
RDH12 (p.Gly127Ter)36, CRB1 (p.Trp1293Ter)37, IQCB1 (p.Arg489Ter)38, and IQCB1 (p.Arg502Ter)38. Similarly, 
we identified three novel frameshift variants, in addition to the previously known frameshift in the ABCA4 
gene (p.Leu296CysfsTer4)39. Novel frameshift variants comprised GUCY2D (p.Ala189ArgfsTer130), RP1 
(p.Val196GlyfsTer33), and USH1G (p.Glu332ThrfsTer53).
Lastly, we detected a novel canonical splice site variant in the RP1 gene (NM_006269.1:c.788-1G > A) in 
family IRN_039, and a known pathogenic synonymous change predicted to alter splicing in the BBS2 gene 
(NM_031885.3:c.471G > A;p.Thr157 =) in family  IRN_06540.
Discussion
Consanguinity is a major risk factor for the occurrence of rare recessive Mendelian disorders, yet it is a long-lived 
social practice in many Asian and African countries. In Iran, the second most populated country in the Middle 
East, 37.4% of all marriages are between consanguineous partners. Of these, 19.3% occur between first cousins 
and 18.1% involve second  cousins7.
In this work, we used consanguinity as a means to facilitate identification of mutations in IRD cases, through 
an autozygome-guided NGS approach. Consistent with the high level of consanguinity displayed by the Iranian 
population, we observed a recessive inheritance pattern in all our cases, with the largest majority of them car-
rying indeed homozygous pathogenic variants in known IRD genes. With only one exception, all genes carry-
ing homozygous pathogenic variants resided inside runs of homozygosity, thus supporting earlier studies that 
highlighted the importance of homozygosity mapping in consanguineous  families41–46. Nevertheless, compound 
heterozygous patients were also identified, with mutations in CRB1 and NMNAT1. Interestingly, these patients 
(from families F009, and IRN_070, respectively) also had relatively lower values of overall genomic homoge-

































































































Scientific Reports |        (2021) 11:19332  | https://doi.org/10.1038/s41598-021-98677-3
www.nature.com/scientificreports/
compound heterozygosity in the Iranian population is not unprecedented, and an earlier study suggested that 
CRB1 is a commonly mutated gene in Iranian patients with non-syndromic  IRDs43,47. Interestingly, our cohort 
did not include any instance of variants in USH2A, although mutations in this gene are considered to be among 
the most frequent causes of Usher syndrome or non-syndromic retinitis pigmentosa (RP)48.
The mutational spectrum in our cohort comprised 1 synonymous (with predicted effect on splicing), 1 splice 
change, 7 missense, 4 nonsense, and 4 frameshift variants. To establish pathogenicity of the novel missense vari-
ants we heavily relied on data from existing literature and the ACMG guidelines. Lastly, we assessed the status 
of each variant by comparing them with the Iranome database, to filter out common variants specific to Iranian 
population.
Unlike missense substitutions, the majority of nonsense and frameshift DNA changes can be considered 
as bona fide deleterious mutations, since they mostly constitute loss-of-function (pLoF) alleles in genes where 
this pathogenicity mechanism is well known (criteria PVS1 of ACMG guidelines). We therefore classified all of 
them as such, based on this feature and the fact that they were all either absent or present at an extremely low 
frequency in the gnomAD database.
We also found a synonymous change in the BBS2 gene (c.471G > A, p.Thr157 =) co-segregating with Bardet-
Biedl syndrome in one family (IRN_065) and reported in three previous  studies40,49,50. Due to the high nucleotide 
conservation and its localization at an exon–intron boundary, it is possible that the c.471G > A substitution may 
impair the correct splicing of BBS2 pre-mRNA. Indeed, all splicing predictors tested (AdaBoost and RandomFor-
est from dbscSNC, MaxEntScan, and spliceAI) indicated a high impact on splicing and disruption of the 5’ site. 
Our findings thus provide additional support to the potential pathogenicity of this apparently neutral variant. 
It is worthwhile to mention here that the majority of the previously reported patients with the p.Thr157 = muta-
tion originated from Middle Eastern countries, such as Lebanon and  Iran49,50. Although this variant perfectly 
co-segregates with disease in family IRN_065 and has been described in previous reports in association with 
Bardet-Biedl  syndrome40,49,50, there is still a chance that it could represent a benign DNA change, detected in 
homozygosity in our patients by virtue of their ethnical origin. Additional functional studies are needed to 
definitely confirm its pathogenic role in syndromic IRD.
Table 1.  List of genetic variants identified in 17 Iranian families. Hom homozygous, Het heterozygous, ROH 
runs of homozygosity, NA not available, Mb megabases.
Family ID Gene name Transcript ID
cDNA 
change Protein change Variant type Zygosity ROH (Mb)
Autozygome 
(Mb)
F003 RDH12 NM_152443.2 c.379G > T p.(Gly127Ter) Nonsense Hom 17.49 324.54
F007 TULP1 NM_003322.5 c.1199G > A p.(Arg400Gln) Missense Hom 21.58 391.04
F009 CRB1 NM_201253.2
c.601T > C p.(Cys201Arg) Missense Het NA 197.05
c.3879G > A p.(Trp1293Ter) Nonsense Het NA 197.05
F021 CNGA3 NM_001298.2 c.848G > A p.(Arg283Gln) Missense Hom 16.5 312.59
F027 RDH12 NM_152443.2 c.715C > T p.(Arg239Trp) Missense Hom 20.78 359.39
F034 TULP1 NM_003322.3 c.1199G > A p.(Arg400Gln) Missense Hom 46.06 220.69
IRN_001 GUCY2D NM_000180.3 c.564dup p.(Ala189ArgfsTer130) Frameshift Hom 21.19 425.35
IRN_004 IQCB1 NM_001023570.3 c.1465C > T p.(Arg489Ter) Nonsense Hom 24.48 285.78
IRN_028 RP1 NM_006269.1 c.584dup p.(Val196GlyfsTer33) Frameshift Hom 4.25 338.69
IRN_033 CNGA3 NM_001298.2 c.830G > A p.(Arg277His) Missense Hom 16.5 242.18
IRN_038 USH1G NM_173477.4 c.980_993dup p.(Glu332ThrfsTer53) Frameshift Hom 10.54 228.74
IRN_039 RP1 NM_006269.1 c.788-1G > A r.spl Splicing Hom NA 213.79
IRN_041 IQCB1 NM_001319107.1 c.1504C > T p.(Arg502Ter) Nonsense Hom 31.84 165.28
IRN_042 GUCY2D NM_000180.3 c.564dup p.(Ala189ArgfsTer130) Frameshift Hom 2.96 322.99
IRN_063 ABCA4 NM_000350.2 c.885del p.(Leu296CysfsTer4) Frameshift Hom 9.94 353.75






c.520A > T p.(Ile174Phe) Missense Het NA 71.41
c.769G > A p.(Glu257Lys) Missense Het NA 71.41
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Since geographic isolation and consanguinity-driven genomic homozygosity lead to the enrichment of rare 
founder mutations in specific societies or ethnic  groups7,9,51,52, the presence of such mutations in our cohort of 
patients from related families is not surprising. Similar to other  reports53–55, we identified two mutations that 
were present in more than one pedigree. The first, p.Ala189ArgfsTer130 in GUCY2D, was shared by two families 
originating from the Fars province in the Southwest of Iran and was found in a common ROH of 3.0 Mb with 
an identical haplotype. The second was a homozygous missense variant (p.Arg400Gln) in the TULP1 gene, 
detected in two families from the Razavi Khorasan province, in Northeastern Iran, again in a common ROH 
of 21.5 Mb with an identical haplotype. This latter variant has been previously reported in an Indian family in 
a homozygous  state33.
In summary, this work extends current knowledge about the genetic landscape of IRDs in Iran and, in line 
with previous studies, supports the evidence that homozygosity mapping is an effective tool for uncovering rare 
genomic variants in consanguineous pedigrees with rare recessive disorders. Most importantly, we hope that our 
data would contribute to better molecular diagnosis and access to future gene therapy trials in Iran.
Table 2.  ClinVar classification, ACMG classification, and other features of all variants identified. NA not 
available.
Family ID Gene name Transcript ID cDNA change Protein change Previous reports ClinVar ACMG ACMG criteria
F003 RDH12 NM_152443.2 c.379G > T p.(Gly127Ter) 36 Pathogenic Pathogenic PVS1, PM2, PP1, PP3, PP5
F007 TULP1 NM_003322.5 c.1199G > A p.(Arg400Gln) 33 Pathogenic Likely pathogenic PM2, PM5, PP1, PP3, PP5
F009 CRB1 NM_201253.2
c.601T > C p.(Cys201Arg) 32 Uncertain signifi-cance Likely pathogenic PM2, PM3, PP1, PP3
c.3879G > A p.(Trp1293Ter) 37 Pathogenic Pathogenic PVS1, PM2, PP1, PP3, PP5
F021 CNGA3 NM_001298.2 c.848G > A p.(Arg283Gln) 31 Pathogenic Likely pathogenic PM1, PM2, PM5, PP1, PP2, PP3, PP5
F027 RDH12 NM_152443.2 c.715C > T p.(Arg239Trp) 34 Likely pathogenic Likely pathogenic PM2, PM5, PP1, PP3, PP5
F034 TULP1 NM_003322.3 c.1199G > A p.(Arg400Gln) 33 Pathogenic Likely pathogenic PM2, PM5, PP1, PP3, PP5
IRN_001 GUCY2D NM_000180.3 c.564dup p.(Ala189Argf-sTer130) Novel NA Pathogenic PVS1, PM2, PP1, PP3
IRN_004 IQCB1 NM_001023570.3 c.1465C > T p.(Arg489Ter) 38 Pathogenic Pathogenic PVS1, PM2, PP1, PP3, PP5
IRN_028 RP1 NM_006269.1 c.584dup p.(Val196GlyfsTer33) Novel NA Pathogenic PVS1, PM2, PP1, PP3
IRN_033 CNGA3 NM_001298.2 c.830G > A p.(Arg277His) 35 Pathogenic Likely pathogenic PM1, PM2, PM5, PP1, PP3, PP5
IRN_038 USH1G NM_173477.4 c.980_993dup p.(Glu332Thrf-sTer53) Novel NA Pathogenic PVS1, PM2, PP1, PP3
IRN_039 RP1 NM_006269.1 c.788-1G > A r.spl Novel NA Pathogenic PVS1, PM2, PP1, PP3
IRN_041 IQCB1 NM_001319107.1 c.1504C > T p.(Arg502Ter) 38 Pathogenic Pathogenic PVS1, PM2, PP1, PP3, PP5
IRN_042 GUCY2D NM_000180.3 c.564dup p.(Ala189Argf-sTer130) Novel NA Pathogenic PVS1, PM2, PP1, PP3
IRN_063 ABCA4 NM_000350.2 c.885del p.(Leu296CysfsTer4) 39 Pathogenic Pathogenic PVS1, PM2, PP1, PP3, PP5
IRN_065 BBS2 NM_031885.3 c.471G > A p.(Thr157 =) 40 Uncertain signifi-cance
Uncertain signifi-
cance PM2, PP1, PP3
IRN_070 NMNAT1 NM_022787.3
c.520A > T p.(Ile174Phe) Novel NA Likely pathogenic PM1, PM2, PM3, PP1, PP2, PP3
c.769G > A p.(Glu257Lys) 30 Pathogenic Likely pathogenic PS3, PM2, PP1, PP2, BP4, PP5
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ABCA4 NM_000350.2 c.885del p.(Leu296Cys-fsTer4) 2.0 ×  10
–5 NA NA NA NA NA NA NA 24.1 NA NA NA NA
BBS2 NM_031885.3 c.471G > A p.(Thr157 =) 1.4 ×  10–5 NA NA NA NA NA NA NA NA
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of donor site 







CNGA3 NM_001298.2 c.848G > A p.(Arg283Gln) 6.4 ×  10–5 NA D D D A H D 28.8 NA NA NA NA
CNGA3 NM_001298.2 c.830G > A p.(Arg277His) 2.4 ×  10–5 NA D D D D H D 28.6 NA NA NA NA
CRB1 NM_201253.2 c.601T > C p.(Cys201Arg) 1.2 ×  10–5 NA D D NA D H D 23.3 NA NA NA NA










NA NA NA NA NA NA NA NA 25.7 NA NA NA NA
IQCB1 NM_001023570.3 c.1465C > T p.(Arg489Ter) 2.8 ×  10–5 NA NA NA N A NA NA 36 NA NA NA NA
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